TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Safety profile: How many participants had an adverse reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Time to Onset of Confirmed Disability Progression (CDP) Sustained for at Least 24 Weeks and 48 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Participants With 24-Week and 48-Week Confirmed Disability Improvement (CDI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Annualized Relapse Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: T cell and antibody mediated acute rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Total Number of Unprotected Anal and Vaginal Sex Occasions
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Improved Caregiver Self-Efficacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Decreased Caregiver Burden
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: Physiological response to intranasal challenge with a food protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Sexual Functioning
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cortical GABA in Anterior Cingulate Cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cortical GABA in Right Anterior Insula
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Alzheimer's Disease Assessment Scale-cognitive Subscale (ADAS-cog)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Quality of Life Scale in Alzheimer's Disease (QOL-AD)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Identification of genetic causes of cardiomyopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Combined endpoint of cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Large local kyphosis angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: High occupying ratio of cross-sectional area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Echocardiographic response to CRT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Frequency of Seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Collection of biological samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in gray matter volume in the somatosensory cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in BOLD (blood oxygen level-dependent) signal in the visual cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percent of Participants With SAE Through Day 30
Endpoint domain: Adverse events/effects
Primary endpoint: Percent of Participants With Grade 3 or 4 AEs Through Day 30
Endpoint domain: Adverse events/effects
Primary endpoint: Percent of Participants Showing a Severe Disease Progression Composite Outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulpal anesthesia effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in alveolar capillary barrier function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reported skin and/or eye reaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Sway
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to separate from VA-ECMO support
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Average Pain at Least
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Average Pain at Worst
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Average Pain
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Early Mortality
Endpoint domain: Mortality/survival
Primary endpoint: patient activation measure
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: patient engagement in health care
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Substance use and mental health outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histamine response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pharmacokinetic parameters of mesalamine and its metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with any Treatment-Emergent Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Baseline to Week 64 in the Sheehan Suicidality Tracking Scale (S-STS) Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from Baseline to Week 52 in the Mini-Mental State Examination (MMSE) Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: maximum serum concentration observed (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the serum concentration versus time curve (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration observed before treatment administration (Ctrough)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of intervention delivery within 4-6 weeks post-discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of dose limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Number of adverse events observed
Endpoint domain: Adverse events/effects
Primary endpoint: Areas of hyperenhanced myocardium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Serum Bactericidal Assay Activity Against Neisseria Meningitidis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of grade 3 or higher xerostomia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of significant desaturations (SpO2 <90% for at least 30 seconds)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pulmonary Artery Mean Pressure (PAPmean) at Rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants With Overall Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Recurrent acute symptomatic DVT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Recurrent acute symptomatic PE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in momentary levels of physiological distress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in momentary levels of suicidal thinking
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of patients colonised with AB-R strains per bacteria species
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of colonising cultures containing AB-R strains per bacteria species
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Anti-MSP1 42 antibody concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Goals of sexual functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Happiness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Anxiety and Depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Heart rate and Heart rate variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Blood pressure/heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cerebral Oxygen Metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Response Rate to Bevacizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Safety of therapies
Endpoint domain: Adverse events/effects
Primary endpoint: Tolerability of efanesoctocog alfa
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of regulatory T-lymphocytes (Tregs) at engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Calf-muscle perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ROM Lumbar spine (Flexion)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: ROM Lumbar spine (Extension)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: ROM Lumbar spine (Side Bending)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Visual Analog Scale <30
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: modified Rankin Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Alpha diversity of scalp microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Beta diversity of scalp microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Calcifications scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: YMCA attendance
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Psychomotor development assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants who uptake clinical breast exam (CBE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of participants who uptake mammography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of participants who uptake pap test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Survival in the intent-to-treat population
Endpoint domain: Mortality/survival
Primary endpoint: Survival in the poor-prognosis patient population
Endpoint domain: Mortality/survival
Primary endpoint: Response rates to invitation to 2nd stage blood test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: stent patency rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Immunogenicity of IPV vaccination schedule
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety and tolerability of hydroxyurea
Endpoint domain: Adverse events/effects
Primary endpoint: Papillary Index (PI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Hb Level of Week 20 and Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Subjects With Hb Level at Each Assessment Time Point Within the Target Range During the Treatment Period
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time to Reach the Target Hb Range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Atrial contractility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Inflammation as indicated by cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in depressed mood as indicated by Hamilton Depression Rating Scale (HAM-D) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Level of prefrontal, limbic and striatal cortex activation as indicated by fMRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in cross sectional area of the Rectus Femoris (RFcsa)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medical Research Council Sum Score (MRC-SS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EQ-5D-5L (Euroscore)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes in joint movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Participants With Neonatal Abstinence Syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Difference in Visual Acuity (Letters)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Non-Ocular Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: HAM-D Score Reduction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: EBA CFU(0-14) rate of change in logCFU per ml sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical fitness/Exercise capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of RFA applications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fatal and nonfatal stroke
Endpoint domain: Mortality/survival
Primary endpoint: Progression of silent brain infarction or white matter lesion on magnetic resonance imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Coronary Calcium Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Infection with organ dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of Participants Achieving ASAS 40 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary ischemic endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Primary bleeding endpoints
Endpoint domain: Adverse events/effects
Primary endpoint: Montgomery Åsberg Depression Rating Scale (MADRS) Rate of Response
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Assess all Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical Global Impressions Scale - Improvement (CGI-I) Response
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: mean score of iFAQ for patients
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: mean score of iFAQ for clinicians
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: muscle mass change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: pre-treatment pain measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy at the margin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Diagnosis performance of initial lesion assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Safety and Tolerability of UE2343
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Plasma Concentration (Cmax) of UE2343
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Cmax (Tmax) of UE2343
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative bioavailability of IV versus SC Administration of LBR-101
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Epicondylar surface movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Sputum Collection Success Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Analysis of immune function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in Systemic Immune Activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean Blood Glucose Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: fasting serum triacylglycerol concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Median Scores on a Subjective Sweet Intensity Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Scores on a Subjective Sweet Intensity Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in TTS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fall risk assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction in intraocular pressure (IOP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Non-inferiority of MAPLe against current ano-rectal physiological tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained virologic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Genetic, behavioral and phenotypic factors related to addiction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants with Ocular and Systemic (Nonocular) Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants with Adverse Events of Special Interest (AESIs) including Ocular AESIs
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Baseline in Early Treatment Diabetic Retinopathy Study - Best Corrected Visual Acuity (ETDRS-BCVA) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to report molecular profiling in tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to report molecular profiling in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of periprosthetic infection (PJI)
Endpoint domain: Adverse events/effects
Primary endpoint: Average Left-Ventricular Wall Thickness-Dimension Ratio Z-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: GI symptoms measured by IBS-SSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: satisfactory relief of IBS symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Complete Spontaneous Bowel Movement (CSBM) Frequency Change From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Dentin sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dental color assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in dialysis adequacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Catheter infection-related incidence rates
Endpoint domain: Adverse events/effects
Primary endpoint: Change across the Impact of Events Scale-Intellectual Disabilities (IES-ID)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Preoperative serum MD2/CysC/DAN Methylation marker/SNPs mutation rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative serum MD2/CysC/DAN Methylation marker value at 24 h after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neuropsychological battery (NPB) assessment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Spatial - temporal gait variables during treadmill walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transition metal concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of novel GnRH secretory patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Identification of non-reproductive phenotypic characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unacceptable Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Dose-Limiting Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Predictability of NeuroSENSE® in airway reflexes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change From Baseline Cognition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes